BioTime, Inc. today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million.
http://ift.tt/P0hjQz
http://ift.tt/P0hjQz
Stem Cell Research News: News on Stem Cell Research continually updated from thousands of sources around from the B Media Network.
No comments:
Post a Comment